SCHEMBL3563200

SCHEMBL3563200

CCCc1cccc(-c2ccccc2)c1[O]

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDCD1 Q15116 1/20 0.46
CD274 Q9NZQ7 1/20 0.46
FOLH1 Q04609 1/20 0.42
DPP4 P27487 1/20 0.42
PPARA Q07869 1/20 0.42
KMT2A Q03164 1/20 0.41
PTGER1 P34995 1/20 0.39
PTGER4 P35408 1/20 0.39
PTGER3 P43115 1/20 0.39
PTGER2 P43116 1/20 0.39
MAPT P10636 1/20 0.36
PTPN1 P18031 1/20 0.36
ADRB2 P07550 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
SOAT1 P35610 2/20 0.36
ELANE P08246 1/20 0.36
CTSG P08311 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4630656 0.89 PDCD1 (0.43) PDCD1CD274FOLH1DPP4PPARA
SCHEMBL4630157 0.88 NR1H2 (0.48) PDCD1CD274PPARASOAT1PTGS2
SCHEMBL3563149 0.86 PDCD1 (0.50) PDCD1CD274FOLH1DPP4PPARA
SCHEMBL4630263 0.86 NR1H2 (0.50) PPARAPTPN1SOAT1
SCHEMBL3569673 0.85 PPARA (0.38) PPARAPTGER1PTGER4PTGER3PTGER2
SCHEMBL607543 0.82 DPP4 (0.56) PDCD1CD274FOLH1DPP4PPARA
Hydrochloric Acid SCHEMBL30641921 0.80 DPP4 (0.54) PDCD1CD274FOLH1DPP4PPARA
SCHEMBL7309326 0.80 GABRA1 (0.44) PPARAELANECTSG
Bicarbonate SCHEMBL1835067 0.79 PPARA (0.56) PDCD1CD274FOLH1DPP4PPARA
SCHEMBL6546839 0.79 CD274 (0.67) PDCD1CD274FOLH1DPP4PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1653960-A4 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN INC (US) 2008-11-26 EP claimed
EP-1653960-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN INC. (US) 2006-05-10 EP claimed
US-20050215526-A1 Melanin concentrating hormone receptor antagonist AMGEN, INC. 2005-09-29 US claimed
WO-2005019167-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN, INC. (US) 2005-03-03 WO claimed
US-7659276-B2 Melanin concentrating hormone receptor antagonist AMGEN, INC. (US) 2010-02-09 US disclosed
US-20090143405-A1 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN, INC. (US) 2009-06-04 US disclosed
US-7514438-B2 Melanin concentrating hormone receptor antagonist AMGEN, INC. (US) 2009-04-07 US disclosed
EP-1653960-A4 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN INC (US) 2008-11-26 EP disclosed
EP-1653960-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN INC. (US) 2006-05-10 EP disclosed
US-20050215526-A1 Melanin concentrating hormone receptor antagonist AMGEN, INC. 2005-09-29 US disclosed
WO-2005019167-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN, INC. (US) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143405-A1 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST MCHR1, MC1R, NPY1R PDCD1 4164/4885CD274 3620/4885FOLH1 2057/4885
US-20050215526-A1 Melanin concentrating hormone receptor antagonist MCHR1, MC1R, NPY1R PDCD1 4164/4885CD274 3620/4885FOLH1 2057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.